Astellas Pharma Inc., Tokyo, Japan.
Astellas Pharma US LLC, Northbrook, IL, USA.
Epidemiol Infect. 2020 Mar 2;148:e65. doi: 10.1017/S0950268820000606.
Clostridioides (Clostridium) difficile infection (CDI) is the leading cause of infectious diarrhoea in hospitalised patients, representing a substantial economic burden driven mainly by increased length of hospital stay (LoS). Currently in Japan, limited evidence on CDI-associated excess LoS is available. We conducted a retrospective, matched-cohort study using a large, Japanese, hospital-based administrative database. CDI was defined as CDI treatment plus either CDI diagnosis or positive enzyme immunoassay result. Propensity score matching at the time of CDI or recurrent CDI (rCDI) onset was applied to adjust baseline confounding and immortal time bias. The analysis included 5 994 054 hospitalisation records during 2008-2017, of which 11 823 were identified as CDI and 1359 as rCDI. The median excess LoS attributable to CDI and rCDI was 3 days and 6.5 days, respectively. The excess mortality attributable to CDI was 6.9%; there was no excess mortality attributable to rCDI (-1.9%). The median difference in costs attributable to CDI and rCDI during the residual stay was JPY 130 296 (USD 1185) and JPY 81 054 (USD 737) per hospitalisation, respectively. By adjusting the biases, the burden of CDI in Japan was evaluated. The findings could support decision making and resource allocation for CDI management in Japanese hospitals.
艰难梭菌(梭状芽孢杆菌)感染(CDI)是住院患者感染性腹泻的主要原因,主要表现为住院时间延长(LoS)增加,造成了巨大的经济负担。目前在日本,与 CDI 相关的超额 LoS 相关证据有限。我们使用一个大型的日本医院管理数据库进行了回顾性匹配队列研究。CDI 的定义为 CDI 治疗加上 CDI 诊断或酶免疫测定阳性结果。在 CDI 或复发性 CDI(rCDI)发病时进行倾向评分匹配,以调整基线混杂和不朽时间偏差。该分析包括 2008 年至 2017 年期间的 5994054 例住院记录,其中 11823 例被确定为 CDI,1359 例为 rCDI。CDI 和 rCDI 分别导致 3 天和 6.5 天的超额 LoS。CDI 导致的超额死亡率为 6.9%;rCDI 没有导致超额死亡率(-1.9%)。CDI 和 rCDI 在剩余住院期间的成本差异中位数分别为 JPY 130296(1185 美元)和 JPY 81054(737 美元)。通过调整偏差,评估了日本 CDI 的负担。这些发现可以为日本医院的 CDI 管理决策和资源分配提供支持。